Stanford University
Stanford, California, 94305, United States
Location status: Recruiting
NCT Number: NCT05996900
Transcranial magnetic stimulation (TMS) is an effective treatment for depression, but clinical outcome is suboptimal, partially because investigators are missing biologically-grounded brain markers which show that TMS is modifying activity at the intended target in the brain. The goal of this proposal is to characterize the key markers of the brain's response to repeated doses of TMS with high resolution using invasive brain recordings in humans, and relate these brain markers to noninvasive recordings. These markers will improve the understanding of TMS and can be used to optimize and enhance clinical efficacy for depression and other psychiatric disorders.
Interested in participating?
Request Info18 year–65 year
All sexes
Interventional
Not applicable
Stanford, California, 94305, United States
Location status: Recruiting
Repetitive transcranial magnetic stimulation (rTMS) is an effective treatment for major depressive disorder, but remission rates are 20-40%, and ideal stimulation parameters are unknown. rTMS is thought to work by changing the synaptic strength of neurons. The ability of the brain to make these changes is referred to as plasticity. rTMS-induced changes are thought to build with successive treatment sessions, a process referred to as metaplasticity. While both plasticity and metaplasticity are well-established in single cell physiology, relevance to rTMS in humans remains unknown. To improve clinical efficacy, the investigators need to understand 1) the neural response to a single rTMS session (plasticity), 2) the neural response to repeated daily rTMS sessions (metaplasticity), and 3) whether computational models of plasticity based on single-cell physiology apply to human patients receiving rTMS for depression.
Goals of the study are to 1) establish a detailed mechanistic understanding of the brain changes during current rTMS treatment; 2) identify clinically meaningful electrophysiological biomarkers for rTMS treatment; 3) establish a computational model to help predict both brain and clinical changes.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Intracranial electrodes will be used for the delivery of invasive brain stimulation.
TMS will be used for the delivery of noninvasive brain stimulation both before and after implantation electrode surgery.
Time frame: 45 minutes
Change in evoked response measured after a single TBS session for active and sham, by resting state iEEG (intracranial EEG) and/or sEEG (stereo EEG).
Time frame: 45 minutes
Change in evoked response measured after a single TBS session for active and sham, by resting state iEEG and/or sEEG.
Time frame: 45 minutes
Change in single-pulse evoked response, or cortico-cortical evoked potentials (CCEPs), measured between two sequential TBS sessions, by resting state iEEG and/or sEEG.
Time frame: 45 minutes
Change in single-pulse evoked response, or cortico-cortical evoked potentials (CCEPs), measured between two sequential TBS sessions, by resting state iEEG and/or sEEG.
Contact information is provided by the study sponsor or research team.
Stanford University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06695767
Brain Diseases, Central Nervous System Diseases
Houston, Texas, United States
View Trial DetailsNCT06159595
Brain Diseases, Central Nervous System Diseases
Stanford, California, United States
View Trial DetailsNCT01590862
Anxiety Disorders, Brain Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT05850689
Depressive Disorder, Depressive Disorder, Major
Huntsville, Alabama, United States
View Trial Details